Side-by-side · Research reference

BPC-157vsGHRP-6

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2Reviewed9/53 cited

BPhase 1Reviewed10/36 cited

BPC-157

Stable Gastric Pentadecapeptide · Healing

250–500 mcgDaily doseHwang 2016

Phase 2Evidence levelHwang 2016 Sikiric 2018

~30 minHalf-life (est.)

SQ or IM · Local · Once or twice daily

GHRP-6

Hexapeptide GHRP · Strong appetite stimulant

100–200 mcgPer doseBowers 1990

Phase 1Evidence levelBowers 1990

~15 minHalf-lifeMalagón 1999

SQ · Multiple sites · 1–3×/day

01Mechanism of Action

Parameter

BPC-157

GHRP-6

Primary target

VEGFR2 / nitric oxide / FAK-paxillin axes (proposed)Chang 2014 Sikiric 2018

Ghrelin receptor (GHS-R1a)Bowers 1990

Pathway

Upregulates VEGFR2 → angiogenesis; modulates NO synthase; promotes fibroblast outgrowth via FAK-paxillinChang 2014

GHS-R1a → Gαq → Ca²⁺ → GH release; central appetite driveBowers 2002

Downstream effect

Accelerated tissue repair, reduced inflammation, improved gut barrier integritySikiric 2018

GH pulse + strong appetite stimulation; modest IGF-1 elevationBowers 2002

Feedback intact?

No known endogenous receptor; mechanism still under investigation

—

Origin

Synthetic pentadecapeptide derived from a sequence in human gastric juice; first characterised by Sikiric et al.Sikiric 2018

Synthetic hexapeptide; first-generation GHRP from Bowers groupBowers 1990

Antibody development

—

02Dosage Protocols

Parameter

BPC-157

GHRP-6

Standard dose

250–500 mcg / dayHwang 2016

Anecdotal community range. Phase 2 trial used 1.0 mg PL-14736 IV/day.

100–200 mcg per injectionBowers 1990

Frequency

Once or twice daily

Split dosing reported anecdotally for chronic injury.

1–3× per day

Lower / starter dose

200 mcg / day

Conservative starter for new users.

50 mcg per dose

Evidence basis

Animal-strong + Phase 2 clinicalSikiric 2018 Hwang 2016

Phase 1 + clinical practiceBowers 1990

Duration

2–4 weeks (acute injury); 4–8 weeks (chronic)

Anecdotal; no long-term human safety data.

8–12 weeks on / 4 off

Reconstitution

Bacteriostatic water, 1–2 mL

Bacteriostatic water

Timing

Local SQ to injury site preferred (anecdotal)

Systemic SQ also used; oral bioavailability shown in animal studies.

Pre-meal preferred for appetite support

Half-life

~30 min plasma (estimated)

Tissue half-life longer; mechanism may explain durable effect.

~15 minMalagón 1999

04Side Effects & Safety

Parameter

BPC-157

GHRP-6

Injection site reaction

Mild irritation (anecdotal)

Mild

GI symptoms

None reported in PL-14736 Phase 2

—

Cardiovascular

Not reported

—

Cancer risk

Theoretical concern via VEGF angiogenesis pathwaySikiric 2018

Contraindicated in active malignancy

Antibody formation

No data (no long-term human trials)

—

Pregnancy / OB

Avoid — insufficient safety data

Avoid

Long-term safety

Unknown beyond Phase 2 trial duration

—

Drug interactions

None established

—

Hunger

—

Pronounced — defining feature vs ipamorelin

Cortisol elevation

—

Mild

Prolactin elevation

—

Mild

Absolute Contraindications

BPC-157

·Pregnancy / breastfeeding
·Known active malignancy (theoretical VEGF concern)

GHRP-6

·Active malignancy
·Pregnancy / breastfeeding

Relative Contraindications

BPC-157

·History of cancer
·Concurrent VEGF inhibitor therapy (theoretical)
·Acute thrombotic events

GHRP-6

·Severe insulin resistance (appetite-driven caloric load)

05Administration Protocol

Parameter

BPC-157

GHRP-6

1. Reconstitution

Add 1–2 mL bacteriostatic water to a 5 mg vial. Roll gently; do not shake. Solution should be clear and colourless.

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.

2. Injection site

Subcutaneous near the injury site is the most common anecdotal route. Systemic SQ (abdomen) also used. Rotate sites.

SQ — abdomen. Rotate sites.

3. Timing

No strict timing requirement. Most users dose once or twice daily, often morning + evening.

Pre-meal for appetite support; pre-sleep for GH alignment.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 30 days.

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

5. Needle

27–31G insulin syringe, 4–8 mm. Local injection allows finer 31G.

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

BPC-157

+ TB-500

Strong

View TB-500 →

BPC-157 and TB-500 (Thymosin β-4) target distinct healing axes: BPC-157 upregulates VEGF-driven angiogenesis and fibroblast migration; TB-500 increases actin remodelling and cell migration via the actin-sequestering β-thymosin domain. Stacked, they cover both vascular (BPC) and structural (TB-500) regeneration pathways. Anecdotally favoured for tendon and ligament repair where both pathways contribute.

BPC-157: 250–500 mcg SQ · daily
TB-500: 2 mg SQ · 2× per week
Primary benefit: Tendon/ligament/muscle repair via complementary angiogenesis + migration

GHRP-6

— no documented stacks